Rep. Katie Porter eviscerates pharma CEO with a brutal math lesson about his $13 million salary

Rep. Katie Porter (D-Calif.) never wastes an opportunity to roast a CEO.

On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee. While at the company, Alles saw a massive increase in the price of the cancer drug Revlimid — and Porter broke down just what it got Alles in return.

Porter started her takedown by asking Alles if he knew what a Revlimid pill cost in 2005: $215, she reminded him with the help of a whiteboard. And by the time Alles left the company late last year, after its sale to Bristol-Myers Squibb, a single Revlimid pill cost $763. “Did the drug get substantially more effective in that time? Did cancer patients need fewer pills?” Porter questioned, trying to figure out why Celgene upped the price. Alles answered by saying Revlimid proved effective in more patients. “So you discovered more patients who might benefit from paying $763 a pill?” Porter rhetorically responded, outlining how the average senior in her district couldn’t even afford one pill.

Porter then moved on to tear apart the $13 million Alles made in 2017 as Celgene’s CEO. “It’s 200 times the average American’s income and 360 times what the average senior makes on Social Security,” Porter noted. She then reminded Alles just how he made “half a million dollars, personally, just by tripling the price of Revlimid.” “The drug didn’t get any better, the cancer patients didn’t get any better, you just got better at making money,” Porter concluded. Watch her questioning below.

More stories from theweek.comChris Wallace is ‘sad’Trump pummels Biden — and AmericaGOP Sen. Tim Scott calls for Trump to correct his Proud Boys comments: ‘If he doesn’t correct it, I guess he didn’t misspeak’